Literature DB >> 31482506

Fibrinolytic Enzymes for Thrombolytic Therapy.

Swaroop S Kumar1, Abdulhameed Sabu2.   

Abstract

Cardiovascular diseases are a group of disorders consisting importantly of coronary heart disease, peripheral arterial disease, cerebrovascular disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis and pulmonary embolism. Severe cardiovascular disease conditions lead to acute myocardial infarction and stroke. One of the reasons for this is formation of blood clots inside the vessel. Anticoagulants and antiplatelet drugs are used for managing cardiovascular diseases for a long time. However, they were unable to dissolve an existing thrombus. Fibrinolytic enzymes have become more substantial for treating cardiovascular diseases since they could lyse the fibrin clot within the blood vessel. Inability of plasma fibrinolytic system demands better thrombolytic drugs. Major thrombolytic enzymes belonging to plasminogen activators and plasmin like enzymes. Currently used fibrinolytic enzymes and their limitations are revisited in the present chapter. Reported enzymes from various sources with potential to be used as cardiovascular therapeutic is also discussed here.

Entities:  

Keywords:  Fibrinolytic enzymes; Microbial thrombolytic enzymes; Nattokinase; Plasminogen activators; Serrapeptase

Mesh:

Substances:

Year:  2019        PMID: 31482506     DOI: 10.1007/978-981-13-7709-9_15

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  242 in total

1.  The mechanism of clot dissolution by plasmin.

Authors:  N ALKJAERSIG; A P FLETCHER; S SHERRY
Journal:  J Clin Invest       Date:  1959-07       Impact factor: 14.808

Review 2.  Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.

Authors:  Ingo Ahrens; Belinda K Smith; Christoph Bode; Karlheinz Peter
Journal:  Expert Opin Drug Metab Toxicol       Date:  2007-08       Impact factor: 4.481

3.  Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.

Authors:  Gregory W Albers; Rüdiger von Kummer; Thomas Truelsen; Jens-Kristian S Jensen; Gabriela M Ravn; Bjørn A Grønning; Hugues Chabriat; Ku-Chou Chang; Antonio E Davalos; Gary A Ford; James Grotta; Markku Kaste; Lee H Schwamm; Ashfaq Shuaib
Journal:  Lancet Neurol       Date:  2015-04-30       Impact factor: 44.182

4.  Purification and some properties of pure Cochliobolus lunatus fibrinolytic Enzyme.

Authors:  A F Abdel-Fattah; A M Ismail
Journal:  Biotechnol Bioeng       Date:  1984-05       Impact factor: 4.530

5.  The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.

Authors:  E Appella; E A Robinson; S J Ullrich; M P Stoppelli; A Corti; G Cassani; F Blasi
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

6.  Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS).

Authors:  P W Armstrong; J R Burton; D Palisaitis; C R Thompson; F Van de Werf; B Rose; D Collen; K K Teo
Journal:  Am Heart J       Date:  2000-05       Impact factor: 4.749

7.  Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).

Authors:  G Agnelli; C Pascucci; G G Nenci; A Mele; R Bürgi; J Heim
Journal:  Thromb Haemost       Date:  1993-08-02       Impact factor: 5.249

8.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Ansell; Jack Hirsh; Elaine Hylek; Alan Jacobson; Mark Crowther; Gualtiero Palareti
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Fibrinolytic serine protease isolation from Bacillus amyloliquefaciens An6 grown on Mirabilis jalapa tuber powders.

Authors:  Rym Agrebi; Noomen Hmidet; Mohamed Hajji; Nawrez Ktari; Anissa Haddar; Nahed Fakhfakh-Zouari; Moncef Nasri
Journal:  Appl Biochem Biotechnol       Date:  2009-10-20       Impact factor: 2.926

10.  Purification and characterization of a serine protease with fibrinolytic activity from the dung beetles, Catharsius molossus.

Authors:  Mi Young Ahn; Bum-Soo Hahn; Kang Sun Ryu; Jin Won Kim; Iksoo Kim; Yeong Shik Kim
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

View more
  2 in total

Review 1.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766

2.  An in vitro Model System for Evaluating Remote Magnetic Nanoparticle Movement and Fibrinolysis.

Authors:  Sebastian P Pernal; Alexander J Willis; Michael E Sabo; Laura M Moore; Steven T Olson; Sean C Morris; Francis M Creighton; Herbert H Engelhard
Journal:  Int J Nanomedicine       Date:  2020-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.